<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Measurement of urinary excretion of endogenous and exogenous glucocorticoids
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Measurement of urinary excretion of endogenous and exogenous glucocorticoids
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Measurement of urinary excretion of endogenous and exogenous glucocorticoids
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Lynnette K Nieman, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Hershel Raff, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            André Lacroix, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Katya Rubinow, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jun 23, 2020.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H518434">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Measurement of urinary excretion of corticosteroids (any steroid hormone produced by the adrenal cortex) and their metabolites has been used to evaluate adrenal function for more than 50 years. Currently, these measurements are used to evaluate cortisol excretion of exogenous glucocorticoids or cortisol and its metabolites in the context of Cushing syndrome or adrenal cancer.
        </p>
        <p>
         Evaluating daily urinary cortisol (and corticosteroid) excretion has the advantage of providing an integrated index of steroid production over a period of 24 hours, whereas measurements of serum cortisol only provide information about an instant in time. This is important because corticotropin (ACTH) and cortisol are secreted in discrete pulses, resulting in plasma concentrations that rise and fall episodically. This is true not only for normal subjects but also for patients with Cushing syndrome caused by pituitary or adrenal tumors [
         <a href="#rid1">
          1,2
         </a>
         ].
        </p>
        <p>
         Other methods of cortisol measurement are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/151.html" rel="external">
          "Establishing the diagnosis of Cushing syndrome"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/161.html" rel="external">
          "Measurement of cortisol in serum and saliva"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/172.html" rel="external">
          "Basic principles in the laboratory evaluation of adrenocortical function"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1622638">
         <span class="h1">
          URINE COLLECTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The validity of the results depends on normal renal function [
         <a href="#rid3">
          3
         </a>
         ]. Individuals with moderate (creatinine clearance less than 60 mL/min) and severe renal impairment (creatinine clearance less than 20 mL/min) have progressively lower cortisol excretion [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
         Additionally, over or under-collection of the 24-hour specimen can bias the results. Because of this, measurement of cortisol excretion must include concurrent measurement of creatinine excretion. The accuracy of the collection (and the reproducibility of a series of collections) can be estimated from knowledge of the normal rate of creatinine excretion (which is equal to creatinine production in the steady state). In adults under the age of 50 years, daily creatinine excretion should be 20 to 25 mg/kg (177 to 221 mmol/kg) lean body weight in men and 15 to 20 mg/kg (133 to 177 mmol/kg) lean body weight in women.
        </p>
        <p>
         From the ages of 50 to 90 years, there is a progressive decline in creatinine excretion (to as low as 10 mg/kg in men), due primarily to a decrease in muscle mass (see
         <a class="medical medical_review" href="/z/d/html/2378.html" rel="external">
          "Calculation of the creatinine clearance"
         </a>
         ). However, the excretion of cortisol and its metabolites varies diurnally, whereas creatinine excretion does not. Thus, inadequate urine collections
         <strong>
          cannot
         </strong>
         be corrected on the basis of the creatinine value. Furthermore, creatinine excretion is not affected by fluid intake, while cortisol excretion increases with increased fluid intake in both children and adults [
         <a href="#rid4">
          4,5
         </a>
         ]. The importance of appropriately timed collection and avoidance of high fluid intake should be stressed to the patient. (See
         <a class="medical medical_patient" href="/z/d/html/2181.html" rel="external">
          "Patient education: Collection of a 24-hour urine specimen (Beyond the Basics)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          24-HOUR URINARY FREE CORTISOL
         </span>
         <span class="headingEndMark">
          —
         </span>
         The 24-hour urinary free cortisol (UFC) is one of the first-line diagnostic tests for Cushing syndrome [
         <a href="#rid6">
          6-9
         </a>
         ]. Serum cortisol measures both cortisol bound to corticosteroid-binding globulin (CBG) and free hormone, while UFC measures only non-CBG-bound cortisol (which is filtered by the kidney unchanged).
         <em>
         </em>
         Therefore, UFC is unaffected by medications and medical conditions that affect CBG, such as oral estrogen use, which increases CBG and serum cortisol concentrations, while UFC is unchanged. (See
         <a class="medical medical_review" href="/z/d/html/160.html" rel="external">
          "Dexamethasone suppression tests", section on 'Sources of error'
         </a>
         .)
        </p>
        <p>
         The use of the 24-hour UFC test in the diagnostic evaluation of Cushing syndrome is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/151.html" rel="external">
          "Establishing the diagnosis of Cushing syndrome", section on '24-hour urinary cortisol excretion'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H177133547">
         <span class="h2">
          Types of assays
         </span>
         <span class="headingEndMark">
          —
         </span>
         We suggest liquid chromatography-tandem mass spectrometry (LC-MS/MS) [
         <a href="#rid10">
          10
         </a>
         ] to measure 24-hour UFC. Normal ranges vary even within analytic methods so it is essential to interpret test results in this context.
        </p>
        <p class="headingAnchor" id="H192363607">
         <span class="h3">
          Antibody based
         </span>
         <span class="headingEndMark">
          —
         </span>
         Some immunoassays are relatively nonspecific because of cross-reaction with other steroids and steroid metabolites (eg,
         <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">
          prednisolone
         </a>
         , the biologically active metabolite of
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         , 6-beta-hydroxycortisol, an inactive metabolite of cortisol and A-ring dihydro- and tetrahydro metabolites [
         <a href="#rid11">
          11-13
         </a>
         ]). This is typically reflected by a higher upper limit of the reference range. Nonspecific urine cortisol immunoassays have reference ranges of 20 to 90 to 100 mcg/day or greater (55 to 250 to 285 nmol/day), considerably higher than the reference ranges for more specific immunoassays and LC-MS/MS (10 to 55 mcg/day [27 to 150 nmol/day]).
        </p>
        <p>
         However, there is significant variability in cross-reactivities between different assays. Online catalogs and laboratory result forms provide the reference range and (sometimes) the test methodology. The laboratory may need to be consulted to investigate unusual or unexpected results. It is prudent to request a referral of such a sample for analysis by LC-MS/MS. Laboratories typically only retain samples for one to two weeks, so fast action by the clinician is needed.
        </p>
        <p>
         Results obtained with nonspecific immunoassays should be interpreted with caution, recognizing the possibility that other glucocorticoids (endogenous and exogenous) and their metabolites are being measured [
         <a href="#rid12">
          12-17
         </a>
         ]. Interestingly, immunoassay crossreactivity may be a diagnostic advantage or, at least, non-inferior for identification of mild glucocorticoid excess [
         <a href="#rid9">
          9,18,19
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h3">
          Structurally based
         </span>
         <span class="headingEndMark">
          —
         </span>
         Urinary cortisol is assayed by structurally based assays that do not use antibodies, such as LC-MS/MS or gas chromatography-mass spectrometry (GC-MS; and previously by high-performance liquid chromatography [HPLC]). These methods are more specific than immunoassays, have a lower reference range (10 to 55 mcg/day [27 to 150 nmol/day]), and correlate well with each other [
         <a href="#rid12">
          12
         </a>
         ]. Most reference laboratories use LC-MS/MS for the evaluation of urinary cortisol and its metabolites and synthetic precursors.
        </p>
        <p class="headingAnchor" id="H177133736">
         <span class="h2">
          Normal values
         </span>
         <span class="headingEndMark">
          —
         </span>
         As noted above, urinary cortisol excretion in normal subjects without excess fluid intake ranges from approximately 10 to 55 mcg/day (27 to 150 nmol/day), measured by specific immunoassays or LC-MS/MS.
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Interpretation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Urinary cortisol excretion results from glomerular filtration of serum free cortisol (unbound minus some that is reabsorbed) and is therefore an index of the integrated 24-hour serum free cortisol concentration. Although urinary cortisol represents less than 1 percent of the cortisol secreted each day, it provides a valid index of cortisol secretion. Because it reflects 24-hour serum cortisol concentrations, one should be suspicious of a high urinary cortisol value in a patient with a normal bedtime serum or salivary cortisol concentration and of a low urinary cortisol value in a patient with a normal morning serum or salivary cortisol concentration.
        </p>
        <p class="headingAnchor" id="H177133931">
         <span class="h3">
          Hypercortisolism
         </span>
         <span class="headingEndMark">
          —
         </span>
         Serum total cortisol concentrations exceed the binding capacity of CBG at approximately 25 mcg/dL, reflecting the normal circadian peak level (690 nmol/L); above this concentration serum free cortisol concentrations increase rapidly, leading to a rapid increase in urinary cortisol excretion.
        </p>
        <p>
         Patients with modest increases in cortisol production may have normal 24-hour UFC. (See
         <a class="medical medical_review" href="/z/d/html/151.html" rel="external">
          "Establishing the diagnosis of Cushing syndrome"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H177133945">
         <span class="h3">
          Adrenal insufficiency and glucocorticoid replacement
         </span>
         <span class="headingEndMark">
          —
         </span>
         Urinary cortisol excretion is low in patients with primary and secondary adrenal insufficiency [
         <a href="#rid20">
          20
         </a>
         ] and in those with congenital adrenal hyperplasia (CAH). However, values in these patients overlap the lower part of the normal reference range. Therefore, UFC alone is not reliable for diagnosis of these conditions.
        </p>
        <p>
         Urinary cortisol assays are not a good indicator of the adequacy of cortisol or cortisone replacement [
         <a href="#rid21">
          21
         </a>
         ]. The same daily replacement dose of cortisol (eg, 30 mg) results in a greater increase in 24-hour urinary cortisol excretion when given as a single dose than when given in multiple divided doses.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A single dose of
         <a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">
          hydrocortisone
         </a>
         is absorbed within 20 to 30 minutes. As a result, serum cortisol concentrations temporarily exceed the binding capacity of CBG and serum free cortisol concentrations are temporarily high. This free cortisol is excreted in the urine until the serum total cortisol concentration, falling rapidly, reaches the binding capacity of CBG.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         When multiple doses are used to give the same total amount of
         <a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">
          hydrocortisone
         </a>
         , serum cortisol concentrations may never exceed the binding capacity of CBG. As a result, the 24-hour urinary cortisol excretion is lower and more representative of the integrated serum free cortisol concentrations to which the patient's cells have been exposed.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H241385854">
         <span class="h2">
          Monitoring adrenal steroidogenesis inhibition for Cushing syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         UFC is used to monitor the efficacy of steroidogenesis inhibitors to decrease cortisol production in Cushing syndrome. When used to monitor inhibitors of CYP11B1 (
         <a class="drug drug_general" data-topicid="10156" href="/z/d/drug information/10156.html" rel="external">
          metyrapone
         </a>
         and
         <a class="drug drug_general" data-topicid="127397" href="/z/d/drug information/127397.html" rel="external">
          osilodrostat
         </a>
         ), LC-MS/MS assays should be used to avoid immunoassay cross-reactivity with increased 11-deoxycortisol resulting from those agents [
         <a href="#rid22">
          22
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/119.html" rel="external">
          "Medical therapy of hypercortisolism (Cushing's syndrome)", section on 'Osilodrostat'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H177133960">
         <span class="h3">
          ACTH/CRH stimulation tests
         </span>
         <span class="headingEndMark">
          —
         </span>
         Urinary cortisol excretion is also disproportionately high after major episodes of endogenous cortisol secretion, as may occur during corticotropin (ACTH) and corticotropin-releasing hormone (CRH) stimulation tests. Because of this, measurement of urinary cortisol excretion for the diagnosis of Cushing syndrome should be avoided after recent administration of these compounds.
        </p>
        <p class="headingAnchor" id="H111252526">
         <span class="h1">
          DETECTING FACTITIOUS OR IATROGENIC CUSHING SYNDROME
         </span>
         <span class="headingEndMark">
          —
         </span>
         The urinary excretion of
         <strong>
          exogenous
         </strong>
         synthetic steroids can be measured using liquid chromatography-tandem mass spectrometry (LC-MS/MS) or gas chromatography-mass spectrometry (GC-MS) [
         <a href="#rid23">
          23,24
         </a>
         ]. This approach can be very helpful in patients suspected of having adrenal suppression or glucocorticoid excess on the basis of iatrogenic or factitious steroid use [
         <a href="#rid25">
          25,26
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H522961">
         <span class="h1">
          OTHER CORTISOL PRECURSORS AND METABOLITES
         </span>
         <span class="headingEndMark">
          —
         </span>
         A variety of other corticosteroids can be measured by mass spectrometry [
         <a href="#rid27">
          27
         </a>
         ]. Some of these involve profiling of multiple steroids (the metabolome) to produce diagnostic "signatures" for congenital adrenal hyperplasia (CAH) [
         <a href="#rid28">
          28
         </a>
         ] or other conditions as below. However, not all are available for clinical use.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Adrenal carcinomas are relatively inefficient producers of steroids and may secrete excessive amounts of several adrenal steroid metabolites and precursors, including androgens (pregnanediol, pregnanetriol, androsterone, etiocholanolone) or glucocorticoids (17-hydroxyproesterone, tetrahydro-11-deoxycortisol, 6-hydroxy-cortisol, tetrahydrocortisol, and alpha-cortol). This pattern distinguishes them from cortisol-secreting adenomas, which produce cortisol, but little androgens [
         <a href="#rid29">
          29-31
         </a>
         ]. Although the method was originally developed using gas chromatography-mass spectrometry (GC-MS), these adrenal urinary steroid panels are now clinically available by liquid chromatography-tandem mass spectrometry (LC-MS/MS) high-resolution accurate mass (HRAM) [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cortisone can be measured in urine by LC-MS/MS [
         <a href="#rid27">
          27,33,34
         </a>
         ]. Its daily excretion is increased in patients with Cushing syndrome; results of this test may be combined with urinary cortisol to aid in the diagnosis of factitious Cushing syndrome produced by ingestion of
         <a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">
          hydrocortisone
         </a>
         . In such patients, urinary cortisol excretion is high, but urinary cortisone excretion is low. It is decreased in patients with the syndrome of apparent mineralocorticoid excess in whom the ratio of urinary cortisol to cortisone may aid in the diagnosis [
         <a href="#rid35">
          35,36
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H177133119">
         <span class="h1">
          OUTMODED ASSAYS FOR MEASUREMENT OF URINARY STEROIDS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Assays for 17-hydroxycorticosteroids, 17-ketogenic steroids, and 17-ketosteroids were previously used for the diagnosis of Cushing syndrome or various types of congenital adrenal hyperplasia (CAH). Because of the availability of more specific assays described above and elsewhere, these are no longer recommended. (See
         <a class="medical medical_review" href="/z/d/html/151.html" rel="external">
          "Establishing the diagnosis of Cushing syndrome"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/145.html" rel="external">
          "Clinical manifestations and diagnosis of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in infants and children"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2075004688">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/112709.html" rel="external">
          "Society guideline links: Diagnosis and treatment of Cushing syndrome"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H15130992">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Measurement of 24-hour urinary cortisol excretion is a first-line test for the diagnosis of hypercortisolism. (See
         <a class="local">
          '24-hour urinary free cortisol'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Urinary free cortisol (UFC) measures only non-corticosteroid binding globulin (CBG)-bound cortisol (which is filtered by the kidney unchanged). Therefore, UFC is unaffected by medications and medical conditions that affect CBG, such as oral estrogen use, which increases CBG and serum cortisol concentrations, while UFC is unchanged. (See
         <a class="local">
          '24-hour urinary free cortisol'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/160.html" rel="external">
          "Dexamethasone suppression tests", section on 'Sources of error'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         UFC is measured by immunoassay or liquid chromatography-tandem mass spectrometry (LC-MS/MS), with the latter being the preferable approach. Clinicians should pay careful attention to the reference ranges for UFC as they vary considerably depending on the assay method used. (See
         <a class="local">
          'Types of assays'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The most important clinical use of 24-hour UFC is for the diagnosis of hypercortisolism and for monitoring the efficacy of steroidogenesis inhibitors. It is not useful for determining adequacy of glucocorticoid replacement regimens. (See
         <a class="local">
          'Hypercortisolism'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/151.html" rel="external">
          "Establishing the diagnosis of Cushing syndrome"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3106136222">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The views expressed in this topic are those of the author(s) and do not reflect the official views or policy of the United States Government or its components.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           van Aken MO, Pereira AM, van Thiel SW, et al. Irregular and frequent cortisol secretory episodes with preserved diurnal rhythmicity in primary adrenal Cushing's syndrome. J Clin Endocrinol Metab 2005; 90:1570.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sandouk Z, Johnston P, Bunch D, et al. Variability of Late-Night Salivary Cortisol in Cushing Disease: A Prospective Study. J Clin Endocrinol Metab 2018; 103:983.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chan KC, Lit LC, Law EL, et al. Diminished urinary free cortisol excretion in patients with moderate and severe renal impairment. Clin Chem 2004; 50:757.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fenske M. Urinary free cortisol and cortisone excretion in healthy individuals: influence of water loading. Steroids 2006; 71:1014.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shi L, Maser-Gluth C, Remer T. Daily urinary free cortisol and cortisone excretion is associated with urine volume in healthy children. Steroids 2008; 73:1446.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elamin MB, Murad MH, Mullan R, et al. Accuracy of diagnostic tests for Cushing's syndrome: a systematic review and metaanalyses. J Clin Endocrinol Metab 2008; 93:1553.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nieman LK, Biller BM, Findling JW, et al. The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2008; 93:1526.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pecori Giraldi F, Ambrogio AG, De Martin M, et al. Specificity of first-line tests for the diagnosis of Cushing's syndrome: assessment in a large series. J Clin Endocrinol Metab 2007; 92:4123.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raff H, Auchus RJ, Findling JW, Nieman LK. Urine free cortisol in the diagnosis of Cushing's syndrome: is it worth doing and, if so, how? J Clin Endocrinol Metab 2015; 100:395.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matsumoto A, Shimanoe C, Tanaka K, et al. Development of suitable method for large-scale urinary glucocorticoid analysis by liquid chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2017; 1057:62.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee C, Goeger DE. Interference of 6 beta-hydroxycortisol in the quantitation of urinary free cortisol by immunoassay and its elimination by solid phase extraction. Clin Biochem 1998; 31:229.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wood L, Ducroq DH, Fraser HL, et al. Measurement of urinary free cortisol by tandem mass spectrometry and comparison with results obtained by gas chromatography-mass spectrometry and two commercial immunoassays. Ann Clin Biochem 2008; 45:380.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fink RS, Pierre LN, Daley-Yates PT, et al. Hypothalamic-pituitary-adrenal axis function after inhaled corticosteroids: unreliability of urinary free cortisol estimation. J Clin Endocrinol Metab 2002; 87:4541.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pearson Murphy BE. Lack of specificity of urinary free cortisol determinations: why does it continue? J Clin Endocrinol Metab 1999; 84:2258.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McCann SJ, Gillingwater S, Keevil BG. Measurement of urinary free cortisol using liquid chromatography-tandem mass spectrometry: comparison with the urine adapted ACS:180 serum cortisol chemiluminescent immunoassay and development of a new reference range. Ann Clin Biochem 2005; 42:112.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fong BM, Tam S, Leung KS. Improved liquid chromatography-tandem mass spectrometry method in clinical utility for the diagnosis of Cushing's syndrome. Anal Bioanal Chem 2010; 396:783.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Persichilli S, Gervasoni J, Iavarone F, Zuppi C. A simple liquid chromatography-tandem mass spectrometry method for urinary free cortisol analysis: suitable for routine purpose. Clin Chem Lab Med 2010; 48:1433.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oßwald A, Wang R, Beuschlein F, et al. Performance of LC-MS/MS and immunoassay based 24-h urine free cortisol in the diagnosis of Cushing's syndrome. J Steroid Biochem Mol Biol 2019; 190:193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ceccato F, Antonelli G, Frigo AC, et al. First-line screening tests for Cushing's syndrome in patients with adrenal incidentaloma: the role of urinary free cortisol measured by LC-MS/MS. J Endocrinol Invest 2017; 40:753.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bornstein SR, Allolio B, Arlt W, et al. Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2016; 101:364.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burch WM. Urine free-cortisol determination. A useful tool in the management of chronic hypoadrenal states. JAMA 1982; 247:2002.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Monaghan PJ, Owen LJ, Trainer PJ, et al. Comparison of serum cortisol measurement by immunoassay and liquid chromatography-tandem mass spectrometry in patients receiving the 11β-hydroxylase inhibitor metyrapone. Ann Clin Biochem 2011; 48:441.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pujos E, Flament-Waton MM, Paisse O, Grenier-Loustalot MF. Comparison of the analysis of corticosteroids using different techniques. Anal Bioanal Chem 2005; 381:244.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taylor RL, Grebe SK, Singh RJ. Quantitative, highly sensitive liquid chromatography-tandem mass spectrometry method for detection of synthetic corticosteroids. Clin Chem 2004; 50:2345.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cizza G, Nieman LK, Doppman JL, et al. Factitious Cushing syndrome. J Clin Endocrinol Metab 1996; 81:3573.
          </a>
         </li>
         <li class="breakAll">
          https://www.mayocliniclabs.com/test-catalog/Overview/81031 (Accessed on May 03, 2020).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schöneshöfer M, Weber B, Oelkers W, et al. Urinary excretion rates of 15 free steroids: potential utility in differential diagnosis of Cushing's syndrome. Clin Chem 1986; 32:93.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Storbeck KH, Schiffer L, Baranowski ES, et al. Steroid Metabolome Analysis in Disorders of Adrenal Steroid Biosynthesis and Metabolism. Endocr Rev 2019; 40:1605.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arlt W, Biehl M, Taylor AE, et al. Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors. J Clin Endocrinol Metab 2011; 96:3775.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bancos I, Arlt W. Diagnosis of a malignant adrenal mass: the role of urinary steroid metabolite profiling. Curr Opin Endocrinol Diabetes Obes 2017; 24:200.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Velikanova LI, Shafigullina ZR, Vorokhobina NV, Malevanaya EV. Gas Chromatography-Mass Spectrometry Analysis of Urinary Steroid Metabolomics for Detection of Early Signs of Adrenal Neoplasm Malignancy in Patients with Cushing's Syndrome. Bull Exp Biol Med 2019; 167:676.
          </a>
         </li>
         <li class="breakAll">
          https://www.mayocliniclabs.com/test-catalog/Overview/604986 (Accessed on May 03, 2020).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lin CL, Wu TJ, Machacek DA, et al. Urinary free cortisol and cortisone determined by high performance liquid chromatography in the diagnosis of Cushing's syndrome. J Clin Endocrinol Metab 1997; 82:151.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taylor RL, Machacek D, Singh RJ. Validation of a high-throughput liquid chromatography-tandem mass spectrometry method for urinary cortisol and cortisone. Clin Chem 2002; 48:1511.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Palermo M, Delitala G, Mantero F, et al. Congenital deficiency of 11beta-hydroxysteroid dehydrogenase (apparent mineralocorticoid excess syndrome): diagnostic value of urinary free cortisol and cortisone. J Endocrinol Invest 2001; 24:17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carvajal CA, Tapia-Castillo A, Vecchiola A, et al. Classic and Nonclassic Apparent Mineralocorticoid Excess Syndrome. J Clin Endocrinol Metab 2020; 105.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 170 Version 20.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15598691" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Irregular and frequent cortisol secretory episodes with preserved diurnal rhythmicity in primary adrenal Cushing's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29329418" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Variability of Late-Night Salivary Cortisol in Cushing Disease: A Prospective Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15044334" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Diminished urinary free cortisol excretion in patients with moderate and severe renal impairment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17010401" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Urinary free cortisol and cortisone excretion in healthy individuals: influence of water loading.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18762206" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Daily urinary free cortisol and cortisone excretion is associated with urine volume in healthy children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18334594" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Accuracy of diagnostic tests for Cushing's syndrome: a systematic review and metaanalyses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18334580" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17698908" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Specificity of first-line tests for the diagnosis of Cushing's syndrome: assessment in a large series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25423573" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Urine free cortisol in the diagnosis of Cushing's syndrome: is it worth doing and, if so, how?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28505491" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Development of suitable method for large-scale urinary glucocorticoid analysis by liquid chromatography-mass spectrometry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9646945" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Interference of 6 beta-hydroxycortisol in the quantitation of urinary free cortisol by immunoassay and its elimination by solid phase extraction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18583623" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Measurement of urinary free cortisol by tandem mass spectrometry and comparison with results obtained by gas chromatography-mass spectrometry and two commercial immunoassays.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12364432" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Hypothalamic-pituitary-adrenal axis function after inhaled corticosteroids: unreliability of urinary free cortisol estimation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10372745" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Lack of specificity of urinary free cortisol determinations: why does it continue?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15829119" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Measurement of urinary free cortisol using liquid chromatography-tandem mass spectrometry: comparison with the urine adapted ACS:180 serum cortisol chemiluminescent immunoassay and development of a new reference range.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19898997" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Improved liquid chromatography-tandem mass spectrometry method in clinical utility for the diagnosis of Cushing's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20604723" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : A simple liquid chromatography-tandem mass spectrometry method for urinary free cortisol analysis: suitable for routine purpose.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30959155" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Performance of LC-MS/MS and immunoassay based 24-h urine free cortisol in the diagnosis of Cushing's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28247215" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : First-line screening tests for Cushing's syndrome in patients with adrenal incidentaloma: the role of urinary free cortisol measured by LC-MS/MS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26760044" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7062507" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Urine free-cortisol determination. A useful tool in the management of chronic hypoadrenal states.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21813575" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Comparison of serum cortisol measurement by immunoassay and liquid chromatography-tandem mass spectrometry in patients receiving the 11β-hydroxylase inhibitor metyrapone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15700162" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Comparison of the analysis of corticosteroids using different techniques.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15486026" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Quantitative, highly sensitive liquid chromatography-tandem mass spectrometry method for detection of synthetic corticosteroids.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8855803" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Factitious Cushing syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8855803" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Factitious Cushing syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3940740" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Urinary excretion rates of 15 free steroids: potential utility in differential diagnosis of Cushing's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31294783" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Steroid Metabolome Analysis in Disorders of Adrenal Steroid Biosynthesis and Metabolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21917861" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28234802" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Diagnosis of a malignant adrenal mass: the role of urinary steroid metabolite profiling.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31630306" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Gas Chromatography-Mass Spectrometry Analysis of Urinary Steroid Metabolomics for Detection of Early Signs of Adrenal Neoplasm Malignancy in Patients with Cushing's Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31630306" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Gas Chromatography-Mass Spectrometry Analysis of Urinary Steroid Metabolomics for Detection of Early Signs of Adrenal Neoplasm Malignancy in Patients with Cushing's Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8989250" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Urinary free cortisol and cortisone determined by high performance liquid chromatography in the diagnosis of Cushing's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12194928" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Validation of a high-throughput liquid chromatography-tandem mass spectrometry method for urinary cortisol and cortisone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11227727" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Congenital deficiency of 11beta-hydroxysteroid dehydrogenase (apparent mineralocorticoid excess syndrome): diagnostic value of urinary free cortisol and cortisone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31909799" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Classic and Nonclassic Apparent Mineralocorticoid Excess Syndrome.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
